DelveInsight's 'Vitiligo - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Vitiligo in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Vitiligo from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Study Period: 2016-2027
Vitiligo - Disease Understanding and Treatment Algorithm
The DelveInsight Vitiligo market report gives the thorough understanding of the Vitiligo by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Vitiligo in the US, Europe, and Japan.
Vitiligo Epidemiology
The Vitiligo epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Prevalent population, Sex specific cases, Diagnosed Cases, Type Specific Diagnosed cases (segmental, non-segmental and unclassified) and Age Specific cases] scenario of Vitiligo in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total prevalent population of Vitiligo was found to be 61, 36,840, in the year 2016.
Vitiligo Drug Chapters
This segment of the Vitiligo report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the therapeutic market of Vitiligo is mainly accounted by the off-label use of Corticosteroids and Calcineurin inhibitors, both as monotherapy as well as combination therapies. Phototherapy is also used in combination with these therapies. Topical Corticosteroids and calcineurin inhibitors constitute the first line of treatment for Vitiligo. Corticosteroids have their own shortcomings, therefore when used in combination with calcineurin inhibitors, they are found to be very much effective in the management of Vitiligo, by resulting in increased repigmentation. Detailed chapters of upcoming therapies such as INCB018424 (Incyte Corporation), and Scenesse (Clinuvel Pharmaceutical) which are expected to get launch during the forecast period have also been covered in the report.
Vitiligo Market Outlook
The Vitiligo market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the total market size of Vitiligo in 7MM was found to be USD 878.5 million in 2016.
Vitiligo Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Vitiligo Report Insights
Vitiligo Report Key Strengths
Vitiligo Report Assessment
Key Benefits
1. Key Insights
2. Vitiligo Market Overview at a Glance
2.1. Market Share (%) Distribution of Vitiligo in 2016
2.2. Market Share (%) Distribution of Vitiligo in 2027
3. Disease Background and Overview: Vitiligo
3.1. Introduction
3.2. Types of Vitiligo
3.3. Causes of Vitiligo
3.4. Symptoms of Vitiligo
3.5. Pathophysiology
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Prevalent Population of Vitiligo in 7MM
5. Country Wise-Epidemiology of Vitiligo
6. United States
6.1. Assumptions and Rationale
6.2. Prevalent Population of Vitiligo in the United States
6.3. Sex Specific Prevalent Population of Vitiligo in the United States
6.4. Diagnosed Cases of Vitiligo in the United States
6.5. Type Specific Diagnosed Prevalent cases of Vitiligo in the United States
6.6. Age Specific Prevalent cases of Vitiligo in the United States
7. EU-5
7.1. Assumptions and Rationale
8. Germany
8.1. Prevalent Population of Vitiligo in Germany
8.2. Sex Specific Prevalent Population of Vitiligo in Germany
8.3. Diagnosed Cases of Vitiligo in Germany
8.4. Type Specific Diagnosed Prevalent cases of Vitiligo in Germany
8.5. Age Specific Prevalent cases of Vitiligo in Germany
9. France
9.1. Prevalent Population of Vitiligo in France
9.2. Sex Specific Prevalent Population of Vitiligo in France
9.3. Diagnosed Cases of Vitiligo in France
9.4. Type Specific Diagnosed Prevalent cases of Vitiligo in France
9.5. Age Specific Prevalent cases of Vitiligo in France
10. Italy
10.1. Prevalent Population of Vitiligo in Italy
10.2. Sex Specific Prevalent Population of Vitiligo in Italy
10.3. Diagnosed Cases of Vitiligo in Italy
10.4. Type Specific Diagnosed Prevalent cases of Vitiligo in Italy
10.5. Age Specific Prevalent cases of Vitiligo in Italy
11. Spain
11.1. Prevalent Population of Vitiligo in Spain
11.2. Sex Specific Prevalent Population of Vitiligo in Spain
11.3. Diagnosed Cases of Vitiligo in Spain
11.4. Type Specific Diagnosed Prevalent cases of Vitiligo in Spain
11.5. Age Specific Prevalent cases of Vitiligo in Spain
12. United Kingdom
12.1. Prevalent Population of Vitiligo in the United Kingdom
12.2. Sex Specific Prevalent Population of Vitiligo in the United Kingdom
12.3. Diagnosed Cases of Vitiligo in the UK
12.4. Type Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom
12.5. Age Specific Prevalent cases of Vitiligo in the UK
13. Japan
13.1. Assumptions and Rationale
13.2. Prevalent Population of Vitiligo in Japan
13.3. Sex Specific Prevalent Population of Vitiligo in Japan
13.4. Diagnosed Cases of Vitiligo in Japan
13.5. Type Specific Diagnosed Prevalent cases of Vitiligo in Japan
13.6. Age Specific Prevalent cases of Vitiligo in Japan
14. Treatment Algorithm
14.1. Treatment Guidelines
14.1.1. American Association of Dermatology (AAD)
14.1.2. The European Dermatology Forum Consensus: Management guidelines for Vitiligo
14.1.3. Vitiligo Japanese Task Force (VJTF); Japanese Dermatological Association: Treatment Guidelines
15. Unmet Needs
16. Emerging Therapies
16.1. INCB018424: Incyte Corporation
16.1.1. Product Description
16.1.2. Other development activities
16.1.3. Clinical Development
16.1.4. Safety and Efficacy
16.1.5. Product Profile
16.2. SCENESSE (afamelanotide): Clinuvel Pharmaceutical
16.2.1. Product Description
16.2.2. Clinical Development
16.2.3. Safety and Efficacy
16.2.4. Product Profile
17. Other Promising Candidates
17.1. ATI-50002: Aclaris Therapeutics
17.1.1. Product Description
17.1.2. Other Development Activities
17.1.3. Clinical Development
17.1.4. Safety and Efficacy
17.1.5. Product Profile
17.2. Apremilast: Celgene
17.2.1. Product Description
17.2.2. Clinical Development
17.2.3. Product Profile
18. Vitiligo: 7 Major Market Analysis
18.1. Key Findings
18.2. Total Market Size of Vitiligo in 7MM
18.3. 7 MM Size of Vitiligo by Therapies
19. Market Outlook by Country
19.1. The United States: Market Outlook
19.2. United States Market Size
19.2.1. Total Market size of Vitiligo
19.2.2. Vitiligo Market Size by Therapies
19.3. EU-5 Countries: Market Outlook
19.4. Germany Market Size
19.4.1. Total Market size of Vitiligo
19.4.2. Vitiligo Market Size by Therapies
19.5. France Market Size
19.5.1. Total Market size of Vitiligo
19.5.2. Vitiligo Market Size by Therapies
19.6. Italy Market Size
19.6.1. Total Market size of Vitiligo
19.6.2. Vitiligo Market Size by Therapies
19.7. Spain Market Size
19.7.1. Total Market size of Vitiligo
19.7.2. Vitiligo Market Size Therapies
19.8. The United Kingdom Market Size
19.8.1. Total Market size of Vitiligo
19.8.2. Vitiligo Market Size by Therapies
19.9. Japan: Market Outlook
19.9.1. Japan: Market Size
19.9.2. Total Market size of Vitiligo
19.9.3. Vitiligo Market Size by Therapies
20. Market Drivers
21. Market Barriers
22. Appendix
23. Report Methodology
23.1. Sources Used
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight
Table 1: Total Prevalent Population of Vitiligo in 7MM (2016-2027)
Table 2: Prevalent Population of Vitiligo in the United States (2016-2027)
Table 3: Sex Specific Prevalent Population of Vitiligo in the United States (2016-2027)
Table 4: Diagnosed cases of Vitiligo in the United States (2016-2027)
Table 5: Type Specific Diagnosed Prevalent cases of Vitiligo in the United States (2016-2027)
Table 6: Age Specific Prevalent cases of Vitiligo in the United States (2018)
Table 7: Prevalent Population of Vitiligo in Germany (2016-2027)
Table 8: Sex Specific Prevalent Population of Vitiligo in Germany (2016-2027)
Table 9: Diagnosed cases of Vitiligo in Germany (2016-2027)
Table 10: Type Specific Diagnosed Prevalent cases of Vitiligo in Germany (2016-2027)
Table 11: Age Specific Prevalent cases of Vitiligo in Germany (2018)
Table 12: Prevalent Population of Vitiligo in France (2016-2027)
Table 13: Sex Specific Prevalent Population of Vitiligo in France (2016-2027)
Table 14: Diagnosed cases of Vitiligo in France (2016-2027)
Table 15: Type Specific Diagnosed Prevalent cases of Vitiligo in France (2016-2027)
Table 16: Age Specific Prevalent cases of Vitiligo in France (2018)
Table 17: Prevalent Population of Vitiligo in Italy (2016-2027)
Table 18: Sex Specific Prevalent Population of Vitiligo in Italy (2016-2027)
Table 19: Diagnosed cases of Vitiligo in Italy (2016-2027)
Table 20: Type Specific Diagnosed Prevalent cases of Vitiligo in Italy (2016-2027)
Table 21: Age Specific Prevalent cases of Vitiligo in Italy (2018)
Table 22: Prevalent Population of Vitiligo in Spain (2016-2027)
Table 23: Sex Specific Prevalent Population of Vitiligo in Spain (2016-2027)
Table 24: Diagnosed cases of Vitiligo in Spain (2016-2027)
Table 25: Type Specific Diagnosed Prevalent cases of Vitiligo in Spain (2016-2027)
Table 26: Age Specific Prevalent cases of Vitiligo in Spain (2018)
Table 27: Prevalent Population of Vitiligo in the United Kingdom (2016-2027)
Table 28: Sex Specific Prevalent Population of Vitiligo in the United Kingdom (2016-2027)
Table 29: Diagnosed cases of Vitiligo in the UK (2016-2027)
Table 30: Type Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2016-2027)
Table 31: Age Specific Prevalent cases of Vitiligo in the UK (2018)
Table 32: Prevalent Population of Vitiligo in Japan (2016-2027)
Table 33: Sex Specific Prevalent Population of Vitiligo in the Japan (2016-2027)
Table 34: Diagnosed cases of Vitiligo in Japan (2016-2027)
Table 35: Type Specific Diagnosed Prevalent cases of Vitiligo in Japan (2016-2027)
Table 36: Age Specific Prevalent cases of Vitiligo in Japan (2018)
Table 37: INCB018424, Clinical Trial Description, 2018
Table 38: SCENESSE, Clinical Trial Description, 2018
Table 39: ATI-50002, Clinical Trial Description, 2018
Table 40: Apremilast, Clinical Trial Description, 2018
Table 41: 7 Major Market Size of Vitiligo in USD Million (2016-2027)
Table 42: 7 Major Market Vitiligo Market Size by Therapies in USD Million (2016-2027)
Table 43: The US Market Vitiligo in USD Million (2016-2027)
Table 44: The US Vitiligo Market Size by Therapies in USD Million (2016-2027)
Table 45: Germany Market Vitiligo in USD Million (2016-2027)
Table 46: Germany Vitiligo Market Size by Therapies in USD Million (2016-2027)
Table 47: France Market Vitiligo in USD Million (2016-2027)
Table 48: France Vitiligo Market Size by Therapies in USD Million (2016-2027)
Table 49: Italy Market Vitiligo in USD Million (2016-2027)
Table 50: Italy Vitiligo Market Size by Therapies in USD Million (2016-2027)
Table 51: The Spain Market Vitiligo in USD Million (2016-2027)
Table 52: Spain Vitiligo Market Size by Therapies in USD Million (2016-2027)
Table 53: The UK Market Vitiligo in USD Million (2016-2027)
Table 54: The UK Vitiligo Market Size by Therapies in USD Million (2016-2027)
Table 55: Japan Market Vitiligo in USD Million (2016-2027)
Table 56:Japan Vitiligo Market Size by Therapies in USD Million (2016-2027)
Figure 1: Types of Vitiligo
Figure 2: Type of Non-segmental Vitiligo
Figure 3: Cellular and Humoral immune mechanisms of Vitiligo
Figure 4: Pathogenesis of Vitiligo
Figure 5: Total Prevalent Population of Vitiligo in 7 MM (2016-2027)
Figure 6: Prevalent Population of Vitiligo in the United States (2016-2027)
Figure 7: Sex Specific Prevalent Population of Vitiligo in the United States (2016-2027)
Figure 8: Diagnosed cases of Vitiligo in the United States (2016-2027)
Figure 9: Type Specific Diagnosed Prevalent cases of Vitiligo in the United States (2016-2027)
Figure 10: Age Specific Prevalent cases of Vitiligo in the United States (2018)
Figure 11: Prevalent Population of Vitiligo in Germany (2016-2027)
Figure 12: Sex Specific Prevalent Population of Vitiligo in Germany (2016-2027)
Figure 13: Diagnosed cases of Vitiligo in the Germany (2016-2027)
Figure 14: Type Specific Diagnosed Prevalent cases of Vitiligo in Germany (2016-2027)
Figure 15: Age Specific Prevalent cases of Vitiligo in Germany (2018)
Figure 16: Prevalent Population of Vitiligo in France (2016-2027)
Figure 17: Sex Specific Prevalent Population of Vitiligo in France (2016-2027)
Figure 18: Diagnosed cases of Vitiligo in France (2016-2027)
Figure 19: Type Specific Diagnosed Prevalent cases of Vitiligo in France (2016-2027)
Figure 20: Age Specific Prevalent cases of Vitiligo in France (2018)
Figure 21: Prevalent Population of Vitiligo in Italy (2016-2027)
Figure 22: Sex Specific Prevalent Population of Vitiligo in Italy (2016-2027)
Figure 23: Diagnosed cases of Vitiligo in Italy (2016-2027)
Figure 24: Type Specific Diagnosed Prevalent cases of Vitiligo in Italy (2016-2027)
Figure 25: Age Specific Prevalent cases of Vitiligo in Italy (2018)
Figure 26: Prevalent Population of Vitiligo in Spain (2016-2027)
Figure 27: Sex Specific Prevalent Population of Vitiligo in Spain (2016-2027)
Figure 28: Diagnosed cases of Vitiligo in Spain (2016-2027)
Figure 29: Type Specific Diagnosed Prevalent cases of Vitiligo in Spain (2016-2027)
Figure 30: Age Specific Prevalent cases of Vitiligo in Spain (2018)
Figure 31: Prevalent Population of Vitiligo in the United Kingdom (2016-2027)
Figure 32: Sex Specific Prevalent Population of Vitiligo in the United Kingdom (2016-2027)
Figure 33: Diagnosed cases of Vitiligo in the United Kingdom (2016-2027)
Figure 34: Type Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2016-2027)
Figure 35: Age Specific Prevalent cases of Vitiligo in the United Kingdom (2018)
Figure 36: Prevalent Population of Vitiligo in Japan (2016-2027)
Figure 37: Sex Specific Prevalent Population of Vitiligo in Japan (2016-2027)
Figure 38: Diagnosed cases of Vitiligo in Japan (2016-2027)
Figure 39: Type Specific Diagnosed Prevalent cases of Vitiligo in Japan (2016-2027)
Figure 40: Age Specific Prevalent cases of Vitiligo in Japan (2018)
Figure 41: Treatment algorithm for Vitiligo
Figure 42: Unmet Needs for Vitiligo
Figure 43: 7 Major Market Size of Vitiligo in USD Million (2016-2027)
Figure 44: 7 Major Market Size of Vitiligo by Therapies in USD Million (2016-2027)
Figure 45: Market Size of Vitiligo in the United States, USD Millions (2016-2027)
Figure 46: The U.S. Vitiligo Market Size by Therapies in USD Million (2016-2027)
Figure 47: Market Size of Vitiligo in the Germany, USD Millions (2016-2027)
Figure 48: Germany Vitiligo Market Size by Therapies in USD Million (2016-2027)
Figure 49: Market Size of Vitiligo in France, USD Millions (2016-2027)
Figure 50: France Vitiligo Market Size by Therapies in USD Million (2016-2027)
Figure 51: Market Size of Vitiligo in Italy, USD Millions (2016-2027)
Figure 52: Italy Vitiligo Market Size by Therapies in USD Million (2016-2027)
Figure 53: Market Size of Vitiligo in Spain, USD Millions (2016-2027)
Figure 54: Spain Vitiligo Market Size by Therapies in USD Million (2016-2027)
Figure 55: Market Size of Vitiligo in UK, USD Millions (2016-2027)
Figure 56: The UK Vitiligo Market Size by Therapies in USD Million (2016-2027)
Figure 57: Market Size of Vitiligo in Japan, USD Millions (2016-2027)
Figure 58: Japan Vitiligo Market Size by Therapies in USD Million (2016-2027)
Figure 59: Market Drivers of Vitiligo
Figure 60:Market Barriers of Vitiligo
